Impact of Insulin-Sensitizing Agents on Reproductive Function in Women with Polycystic Ovary Syndrome
DOI:
https://doi.org/10.12775/JEHS.2026.89.69896Keywords
Polycystic Ovary Syndrome, Insulin resistance, Insulin sensitizers, Myo-inositol, Metformin, Fertility, Reproductive outcomes, Ovulation induction, HyperandrogenismAbstract
Background. Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age, which collectively impair fertility. Insulin-sensitizing agents have emerged as a key therapeutic strategy to improve metabolic, hormonal, and reproductive outcomes in this population.
Aim. This review critically evaluates current evidence on insulin-sensitizing agents in women with PCOS, addressing both their mechanisms of action at the metabolic and ovarian levels and their effects on reproductive outcomes.
Material and Methods. A review of randomized controlled trials, meta-analyses, and high-quality observational studies published up to 2025 evaluated the effects of metformin, myo-inositol, and berberine on reproductive outcomes in women with PCOS.
Results. Insulin-sensitizing agents improve metabolic dysfunction and ovulatory outcomes in PCOS. Metformin increases ovulation and clinical pregnancy rates, particularly in women with insulin resistance or higher BMI, though its effect on live birth is inconsistent. Myo-inositol and berberine show beneficial effects on metabolic parameters and ovulatory function, but evidence for live birth and miscarriage remains limited.
Conclusions. Insulin-sensitizing therapies support reproductive function in women with PCOS, particularly in metabolically compromised phenotypes. Metformin has the strongest evidence base, whereas myo-inositol and berberine are promising adjunctive or alternative options. Future high-quality randomized trials focusing on live birth and miscarriage outcomes, standardized reporting, and precise patient stratification are needed to optimize the clinical use of these agents in PCOS-related infertility.
References
1. Ehrmann DA. Polycystic Ovary Syndrome. New England Journal of Medicine 2005;352:1223–36.
2. Zhang D, Yang X, Li J et al. Effect of hyperinsulinaemia and insulin resistance on endocrine, metabolic and fertility outcomes in women with polycystic ovary syndrome undergoing ovulation induction. Clin Endocrinol (Oxf) 2019;91:440–8.
3. Jin Y, Sun F, Yang A et al. Insulin-like growth factor binding protein-1 and insulin in polycystic ovary syndrome: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2023;14:1279717.
4. Kazerooni T, Ghaffarpasand F, Asadi N et al. Correlation between thrombophilia and recurrent pregnancy loss in patients with polycystic ovary syndrome: A comparative study. Journal of the Chinese Medical Association 2013;76:282–8.
5. Moore AM. Neuroendocrine mechanisms responsible for elevated gonadotrophin-releasing hormone and luteinising hormone pulses in polycystic ovary syndrome. J Neuroendocrinol 2025;37, DOI: 10.1111/JNE.70028.
6. Rudnicka E, Kunicki M, Calik-Ksepka A et al. Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS. Int J Mol Sci 2021;22:12507.
7. Pellatt L, Rice S, Dilaver N et al. Anti-Müllerian hormone reduces follicle sensitivity to follicle-stimulating hormone in human granulosa cells. Fertil Steril 2011;96, DOI: 10.1016/j.fertnstert.2011.08.015.
8. Zhao H, Zhang J, Cheng X et al. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. Journal of Ovarian Research 2023 16:1 2023;16:9-.
9. Gholinezhad M, Gholsorkhtabaramiri M, Esmaeilzadeh S et al. Insulin resistance and adverse metabolic profile in overweight/obese and normal weight of young women with polycystic ovary syndrome. Caspian J Intern Med 2018;9:260–7.
10. Houston EJ, Templeman NM. Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS. J Endocrinol 2025;265, DOI: 10.1530/JOE-24-0269.
11. Wei SY, Zhang JL, Guan HQ et al. High androgen level during controlled ovarian stimulation cycle impairs endometrial receptivity in PCOS patients. Scientific Reports 2024 14:1 2024;14:23100-.
12. Su P, Chen C, Sun Y. Physiopathology of polycystic ovary syndrome in endocrinology, metabolism and inflammation. Journal of Ovarian Research 2025 18:1 2025;18:34-.
13. Kicińska AM, Maksym RB, Zabielska-Kaczorowska MA et al. Immunological and Metabolic Causes of Infertility in Polycystic Ovary Syndrome. Biomedicines 2023, Vol 11, Page 1567 2023;11:1567.
14. Balogh Z, Csehely S, Orosz M et al. Relations of Insulin Resistance, Body Weight, Vitamin D Deficiency, SHBG and Androgen Levels in PCOS Patients. Biomedicines 2025;13, DOI: 10.3390/BIOMEDICINES13081803.
15. Houston EJ, Templeman NM. Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS. J Endocrinol 2025;265, DOI: 10.1530/JOE-24-0269.
16. Allahbadia GN, Merchant R. Polycystic ovary syndrome and impact on health. Middle East Fertil Soc J 2011;16:19–37.
17. Franks S, McCarthy MI, Hardy K et al. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl 2006;29:278–85.
18. McCartney CR, Marshall JC. Polycystic Ovary Syndrome. N Engl J Med 2016;375:54.
19. Kashyap S, Wells GA, Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod 2004;19:2474–83.
20. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617–23.
21. Falbo A, Orio F, Venturella R et al. Does metformin affect ovarian morphology in patients with polycystic ovary syndrome? A retrospective cross-sectional preliminary analysis. J Ovarian Res 2009;2, DOI: 10.1186/1757-2215-2-5.
22. Sonntag B, Götte M, Wülfing P et al. Metformin alters insulin signaling and viability of human granulosa cells. Fertil Steril 2005;84:1173–9.
23. Palomba S, Falbo A, Russo T et al. Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. Hum Reprod 2010;25:1005–13.
24. Palomba S, Falbo A, La Sala GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG 2013;120:267–76.
25. Palomba S, Russo T, Orio F et al. Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. Hum Reprod 2006;21:457–65.
26. Costello MF, Eden JA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003;79:1–13.
27. Velázquez M. E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstetrics and Gynecology 1997;90:392–5.
28. Costello MF, Eden JA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003;79:1–13.
29. Siebert TI, Viola MI, Steyn DW et al. Is Metformin Indicated as Primary Ovulation Induction Agent in Women with PCOS? A Systematic Review and Meta-Analysis. Gynecol Obstet Invest 2012;73:304–13.
30. Tsiami AP, Goulis DG, Sotiriadis AI et al. Higher ovulation rate with letrozole as compared with clomiphene citrate in infertile women with polycystic ovary syndrome: a systematic review and meta-analysis. Hormones (Athens) 2021;20:449–61.
31. Franik S, Le QK, Kremer JAM et al. Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2022;9, DOI: 10.1002/14651858.CD010287.PUB4.
32. Miller KAR, Pinheiro GM. Comparative Outcomes of Letrozole Versus Clomiphene Citrate for Ovulation Induction in Patients With PCOS: Systematic Review and Meta-Analysis. JBRA Assist Reprod 2025:1–14.
33. Kazerooni T, Ghaffarpasand F, Kazerooni Y et al. Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. Int J Gynaecol Obstet 2009;107:50–3.
34. Azargoon A, Toussy JA, Darbanan FF. Pregnancies following the use of sequential treatment of metformin and incremental doses of letrozole in clomiphen-resistant women with polycystic ovary syndrome. Iran J Reprod Med 2012;10:33.
35. Sohrabvand F, Ansari S, Bagheri M. Efficacy of combined metformin-letrozole in comparison with metformin-clomiphene citrate in clomiphene-resistant infertile women with polycystic ovarian disease. Hum Reprod 2006;21:1432–5.
36. Mahoney A, D’Angelo A. Treatment Options for Managing Anovulation in Women with PCOS: An Extensive Literature Review of Evidence-Based Recommendations for Future Directions. 2025;15:863.
37. Weiss NS, Kostova EB, Mol BWJ et al. Gonadotropins for ovulation induction in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2025;4, DOI: 10.1002/14651858.CD010290.PUB4.
38. Vyrides AA, El Mahdi E, Giannakou K. Ovulation induction techniques in women with polycystic ovary syndrome. Front Med (Lausanne) 2022;9:982230.
39. Palomba S, Falbo A, La Sala GB. Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials. Reprod Biol Endocrinol 2014;12:3.
40. Stadtmauer LA, Toma SK, Riehl RM et al. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril 2001;75:505–9.
41. Tso LO, Costello MF, Albuquerque LET et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2020;2020, DOI: 10.1002/14651858.CD006105.PUB4.
42. Wu Y, Tu M, Huang Y et al. Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis. JAMA Netw Open 2020;3:e2011995.
43. Elia EM, Quintana R, Carrere C et al. Metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study. J Ovarian Res 2013;6, DOI: 10.1186/1757-2215-6-62.
44. Lin L, Chen G, Qiao X et al. Comparative efficacy and safety of metformin, anti-obesity agents, and myoinositol in improving IVF/ICSI outcomes and reducing ovarian hyperstimulation syndrome in women with polycystic ovary syndrome: a systematic review and network meta-analysis. J Ovarian Res 2024;17, DOI: 10.1186/S13048-024-01576-0.
45. Saadati S, Mason T, Godini R et al. Metformin use in women with polycystic ovary syndrome (PCOS): Opportunities, benefits, and clinical challenges. Diabetes Obes Metab 2025;27:31.
46. Attia GM, Almouteri MM, Alnakhli FT. Role of Metformin in Polycystic Ovary Syndrome (PCOS)-Related Infertility. Cureus 2023;15:e44493.
47. Toosy S, Sodi R, Pappachan JM. Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach. J Diabetes Metab Disord 2018;17:277.
48. Laganà AS, Garzon S, Casarin J et al. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach. Trends in Endocrinology and Metabolism 2018;29:768–80.
49. Inositol: history of an effective therapy for Polycystic Ovary Syndrome - PubMed.
50. Song G, Liu N, He J et al. Exploring the role of Myo-inositol in alleviating insulin resistance in polycystic ovary syndrome through the AMPK/GLUT4 pathway. Mol Biol Rep 2025;52, DOI: 10.1007/S11033-025-10553-9.
51. Cabrera-Cruz H, Oróstica L, Plaza-Parrochia F et al. The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment. Am J Physiol Endocrinol Metab 2020;318:E237–48.
52. Zhang Y, Li C, Zhang W et al. Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model. J Med Food 2020;23:375–87.
53. Baptiste CG, Battista MC, Trottier A et al. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 2009;122:42.
54. Godaneh MK, Rahimi S, Abizadeh M et al. Insulin Ameliorates Folliculogenesis in An Experimental Model of PCOS Mice. Int J Fertil Steril 2023;17:22–7.
55. Yang W, Pang N, He X. Breaking the metabolic–inflammatory vicious cycle in polycystic ovary syndrome: a comparative review of ketogenic and high-fat diets. Lipids Health Dis 2025;24:310.
56. Koleva-Tyutyundzhieva D, Ilieva-Gerova M, Deneva T et al. Metabolic and Inflammatory Adipokine Profiles in PCOS: A Focus on Adiposity, Insulin Resistance, and Atherogenic Risk. International Journal of Molecular Sciences 2025, Vol 26, Page 9702 2025;26:9702.
57. Wang C, Wen Y-X, Mai Q-Y. Impact of metabolic disorders on endometrial receptivity in patients with polycystic ovary syndrome. Exp Ther Med 2022;23, DOI: 10.3892/ETM.2022.11145.
58. Fitz V, Graca S, Mahalingaiah S et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. J Clin Endocrinol Metab 2024;109:1630.
59. Pundir J, Psaroudakis D, Savnur P et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG 2018;125:299–308.
60. Fitz V, Graca S, Mahalingaiah S et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. J Clin Endocrinol Metab 2024;109:1630–55.
61. Greff D, Juhász AE, Váncsa S et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol 2023;21, DOI: 10.1186/S12958-023-01055-Z.
62. Laganà AS, Rossetti P, Buscema M et al. Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols. Int J Endocrinol 2016;2016, DOI: 10.1155/2016/6306410.
63. Garg D, Tal R. Inositol Treatment and ART Outcomes in Women with PCOS. Int J Endocrinol 2016;2016:1979654.
64. Cao RY, Zheng Y, Zhang Y et al. Berberine on the Prevention and Management of Cardiometabolic Disease: Clinical Applications and Mechanisms of Action. Am J Chin Med (Gard City N Y) 2021;49:1645–66.
65. Lee YS, Kim WS, Kim KH et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006;55:2256–64.
66. Li W, Li D, Kuang H et al. Berberine increases glucose uptake and intracellular ROS levels by promoting Sirtuin 3 ubiquitination. Biomedicine & Pharmacotherapy 2020;121:109563.
67. Zhang N, Liu X, Zhuang L et al. Berberine decreases insulin resistance in a PCOS rats by improving GLUT4: Dual regulation of the PI3K/AKT and MAPK pathways. Regulatory Toxicology and Pharmacology 2020;110, DOI: 10.1016/j.yrtph.2019.104544.
68. Xie L, Zhang D, Ma H et al. The Effect of Berberine on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Control Trials. Evid Based Complement Alternat Med 2019;2019:7918631.
69. Li L, Xiao Y, Zhou J et al. Effects of Berberine on glucolipid metabolism among dehydroepiandrosterone-induced rats of polycystic ovary syndrome with insulin-resistance. Heliyon 2024;10, DOI: 10.1016/j.heliyon.2024.e24338.
70. Huang Y, Li W, Wang CC et al. Cryptotanshinone reverses ovarian insulin resistance in mice through activation of insulin signaling and the regulation of glucose transporters and hormone synthesizing enzymes. Fertil Steril 2014;102, DOI: 10.1016/j.fertnstert.2014.05.012.
71. Cao RY, Zheng Y, Zhang Y et al. Berberine on the Prevention and Management of Cardiometabolic Disease: Clinical Applications and Mechanisms of Action. Am J Chin Med (Gard City N Y) 2021;49:1645–66.
72. García-Muñoz AM, Victoria-Montesinos D, Ballester P et al. A Descriptive Review of the Antioxidant Effects and Mechanisms of Action of Berberine and Silymarin. Molecules 2024, Vol 29, Page 4576 2024;29:4576.
73. Cai WY, Luo X, Ma HL et al. Association between preconception serum lipid concentrations and treatment outcomes in women with PCOS who underwent ovulation induction. Reprod Biomed Online 2022;45:805–14.
74. Jiang H, Si M, Tian T et al. Adiposity and lipid metabolism indicators mediate the adverse effect of glucose metabolism indicators on oogenesis and embryogenesis in PCOS women undergoing IVF/ICSI cycles. Eur J Med Res 2023;28:216.
75. Shen HR, Xu X, Ye D et al. Berberine Improves the Symptoms of DHEA-Induced PCOS Rats by Regulating Gut Microbiotas and Metabolites. Gynecol Obstet Invest 2021;86:388–97.
76. Zhang F, Ma T, Cui P et al. Diversity of the gut microbiota in dihydrotestosterone-induced PCOS rats and the pharmacologic effects of diane-35, probiotics, and berberine. Front Microbiol 2019;10:418898.
77. Zhang X, Zhao Y, Zhang M et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One 2012;7, DOI: 10.1371/JOURNAL.PONE.0042529.
78. Lu Y, Zhang X, He J et al. The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta analysis of randomized controlled trials. Inflammopharmacology 2022;30:1063–77.
79. He S, Li H, Zhang Q et al. Berberine alleviates inflammation in polycystic ovary syndrome by inhibiting hyaluronan synthase 2 expression. Phytomedicine 2024;128, DOI: 10.1016/j.phymed.2024.155456.
80. Wu XK, Wang YY, Liu JP et al. Randomized controlled trial of letrozole, berberine, or a combination for infertility in the polycystic ovary syndrome. Fertil Steril 2016;106:757-765.e1.
81. Di Maio V, Bouteiller JMC. Editorial: Influence of Inter- and Intra-Synaptic Factors on Information Processing in the Brain. Front Comput Neurosci 2019;13, DOI: 10.3389/FNCOM.2019.00032.
82. Xie L, Zhang D, Ma H et al. The Effect of Berberine on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Control Trials. Evid Based Complement Alternat Med 2019;2019:7918631.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Magdalena Korba, Katarzyna Tłustochowicz, Natalia Malicka, Karolina Łuczak, Agnieszka Krajewska, Wiktoria Polkowska, Adrianna Kowalik, Agnieszka Korzeniewska, Julia Dębczak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 105
Number of citations: 0
